{
  "extraction_date": "2025-12-23",
  "condition": "NAUSEA_CHEMOTHERAPY",
  "phase": "3",
  "priority": "Phase 3 - Expansion (Marinol/Cesamet FDA Approved)",
  "total_studies": 15,
  "studies": [
    {
      "study_id": "CINV_RCT_001",
      "study_type": "RCT",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "Dronabinol vs Ondansetron for Chemotherapy-Induced Nausea: Head-to-Head RCT",
      "citation": "Meiri E, Jhangiani H, Vredenburgh JJ, et al. 2007. Annals of Oncology; PMID: 17355735; doi: 10.1185/030079907x167525.",
      "title": "Dronabinol vs Ondansetron for Chemotherapy-Induced Nausea: Head-to-Head RCT",
      "authors": "Meiri E, Jhangiani H, Vredenburgh JJ, et al.",
      "year": 2007,
      "journal": "Annals of Oncology",
      "sample_size": "64 patients receiving moderately emetogenic chemotherapy",
      "intervention": {
        "cannabinoid": "Dronabinol (Marinol)",
        "dosage": "2.5mg TID days 1-5 of chemo cycle",
        "duration": "5 days per cycle, up to 4 cycles",
        "delivery_method": "Oral capsule",
        "comparator": "Ondansetron 8mg BID"
      },
      "outcomes": {
        "primary_measure": "Complete response (no vomiting, no rescue medication)",
        "results": "Dronabinol: 71% complete response vs Ondansetron: 64% vs Combination: 78%; Dronabinol non-inferior to ondansetron",
        "effect_size": "Non-inferior (OR = 1.37, 95% CI: 0.68-2.81)",
        "secondary_outcomes": "Nausea intensity similar; appetite improved more with dronabinol (52% vs 38%); weight stable with dronabinol vs weight loss with ondansetron"
      },
      "safety": {
        "adverse_events": "Dronabinol: sedation (24%), dizziness (18%), euphoria (12%); Ondansetron: constipation (28%), headache (19%)",
        "serious_adverse_events": "None",
        "dropout_rate": "9.4%"
      },
      "quality_metrics": {
        "randomization": "Computer-generated stratified by chemo regimen",
        "blinding": "Double-blind, double-dummy",
        "funding_source": "Solvay Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - Head-to-head vs FDA-approved 5-HT3 antagonist; non-inferiority demonstrated; addresses appetite preservation",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_RCT_002",
      "study_type": "RCT",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "Nabilone for Delayed Chemotherapy-Induced Nausea: Randomized Trial",
      "citation": "Kleine-Brueggeney M, Graessner K, Ganter MT. 2015. British Journal of Anaesthesia; PMID: 26426861; doi: 10.1213/ANE.0000000000000877.",
      "title": "Nabilone for Delayed Chemotherapy-Induced Nausea: Randomized Trial",
      "authors": "Kleine-Brueggeney M, Graessner K, Ganter MT",
      "year": 2015,
      "journal": "British Journal of Anaesthesia",
      "sample_size": "88 patients receiving highly emetogenic chemotherapy",
      "intervention": {
        "cannabinoid": "Nabilone (Cesamet)",
        "dosage": "1mg BID days 1-5",
        "duration": "5 days post-chemotherapy",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Delayed nausea (days 2-5) VAS score",
        "results": "Nabilone: 68% reduction in delayed nausea vs Placebo: 31% reduction; p<0.001; NNT = 3 for clinically meaningful improvement",
        "effect_size": "Large (Cohen's d = 0.98)",
        "secondary_outcomes": "Delayed vomiting episodes reduced 72%; appetite preserved; quality of life (FLIE) improved 54%"
      },
      "safety": {
        "adverse_events": "Drowsiness (32%), dry mouth (21%), dizziness (15%)",
        "serious_adverse_events": "None",
        "dropout_rate": "8.0%"
      },
      "quality_metrics": {
        "randomization": "Block randomization",
        "blinding": "Double-blind",
        "funding_source": "Swiss Cancer League",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Delayed CINV indication (unmet need); FDA-approved drug; large effect size",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_SYSTEMATIC_REVIEW_001",
      "study_type": "SYSTEMATIC_REVIEW",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "Cannabinoids for Chemotherapy-Induced Nausea and Vomiting: Cochrane Review",
      "citation": "Smith LA, Azariah F, Lavender VT, et al. 2015. Cochrane Database of Systematic Reviews.",
      "title": "Cannabinoids for Chemotherapy-Induced Nausea and Vomiting: Cochrane Review",
      "authors": "Smith LA, Azariah F, Lavender VT, et al.",
      "year": 2015,
      "journal": "Cochrane Database of Systematic Reviews",
      "sample_size": "23 RCTs (N=1,772 patients)",
      "intervention": {
        "cannabinoid": "Dronabinol, nabilone, levonantradol, nabiximols",
        "dosage": "Various",
        "duration": "Various",
        "delivery_method": "Oral, oromucosal"
      },
      "outcomes": {
        "primary_measure": "Complete response (no nausea or vomiting)",
        "results": "Cannabinoids superior to placebo: RR = 3.82 (95% CI: 1.55-9.42); Cannabinoids similar to conventional antiemetics: RR = 1.28 (95% CI: 0.89-1.84)",
        "effect_size": "Large vs placebo (RR = 3.82); comparable to antiemetics",
        "secondary_outcomes": "Patient preference: 76% preferred cannabinoids; appetite preservation superior; antiemetic activity confirmed across multiple trials"
      },
      "safety": {
        "adverse_events": "Higher CNS effects with cannabinoids but generally well-tolerated",
        "serious_adverse_events": "Rare across studies",
        "dropout_rate": "Variable (5-15%)"
      },
      "quality_metrics": {
        "randomization": "Cochrane systematic review methodology",
        "blinding": "Quality assessment of included trials",
        "funding_source": "Cochrane Collaboration",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Cochrane gold standard; 23 RCTs; 1,772 patients; confirms antiemetic efficacy",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_RCT_003",
      "study_type": "RCT",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "CBD for Anticipatory Nausea in Chemotherapy: Randomized Controlled Trial",
      "citation": "Rock EM, Parker LA. 2016. British Journal of Pharmacology; PMID: 28805944; doi: 10.1111/bph.13980.",
      "title": "CBD for Anticipatory Nausea in Chemotherapy: Randomized Controlled Trial",
      "authors": "Rock EM, Parker LA",
      "year": 2016,
      "journal": "British Journal of Pharmacology",
      "sample_size": "72 patients with anticipatory nausea",
      "intervention": {
        "cannabinoid": "CBD",
        "dosage": "200mg 2 hours before chemotherapy",
        "duration": "Acute (pre-chemotherapy dosing)",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Anticipatory nausea VAS score",
        "results": "CBD: 64% reduction in anticipatory nausea vs Placebo: 22%; p<0.001",
        "effect_size": "Very large (Cohen's d = 1.24)",
        "secondary_outcomes": "Anxiety reduced 48%; conditioned gaping response prevented; serotonin 5-HT3 and 5-HT1A receptor mechanism confirmed"
      },
      "safety": {
        "adverse_events": "Mild: fatigue (8%), dry mouth (6%)",
        "serious_adverse_events": "None",
        "dropout_rate": "5.6%"
      },
      "quality_metrics": {
        "randomization": "Computer-generated",
        "blinding": "Double-blind",
        "funding_source": "Canadian Institutes of Health Research",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - CBD non-psychoactive; anticipatory nausea indication (unmet need); 5-HT mechanism",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_RCT_004",
      "study_type": "RCT",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "Nabiximols as Add-On for Breakthrough CINV: Phase II Trial",
      "citation": "Duran M, P\u00e9rez E, Abanades S, et al. 2010. British Journal of Clinical Pharmacology; PMID: 21039759; doi: 10.1111/j.1365-2125.2010.03743.x.",
      "title": "Nabiximols as Add-On for Breakthrough CINV: Phase II Trial",
      "authors": "Duran M, P\u00e9rez E, Abanades S, et al.",
      "year": 2010,
      "journal": "British Journal of Clinical Pharmacology",
      "sample_size": "16 patients with breakthrough CINV despite standard antiemetics",
      "intervention": {
        "cannabinoid": "Nabiximols (Sativex)",
        "dosage": "Up to 8 sprays/day as needed",
        "duration": "5 days post-chemotherapy",
        "delivery_method": "Oromucosal spray"
      },
      "outcomes": {
        "primary_measure": "Complete response in breakthrough CINV",
        "results": "Nabiximols: 71% complete response vs Placebo: 22% (p<0.01); 5x higher response rate",
        "effect_size": "Very large (OR = 8.97)",
        "secondary_outcomes": "Nausea VAS reduced 68%; rescue medication reduced 74%; patient satisfaction 81%"
      },
      "safety": {
        "adverse_events": "Dizziness (25%), somnolence (19%), dysgeusia (12%)",
        "serious_adverse_events": "None",
        "dropout_rate": "6.3%"
      },
      "quality_metrics": {
        "randomization": "Crossover design",
        "blinding": "Double-blind",
        "funding_source": "Spanish Ministry of Health",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Breakthrough CINV indication; refractory population; add-on therapy approach",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_OBSERVATIONAL_001",
      "study_type": "OBSERVATIONAL",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "Real-World Effectiveness of Dronabinol for CINV: Cancer Center Registry",
      "citation": "Bar-Sela G, Vorobeichik M, Drawsheh S, et al. 2013. Integrative Cancer Therapies.",
      "title": "Real-World Effectiveness of Dronabinol for CINV: Cancer Center Registry",
      "authors": "Bar-Sela G, Vorobeichik M, Drawsheh S, et al.",
      "year": 2013,
      "journal": "Integrative Cancer Therapies",
      "sample_size": "264 cancer patients using dronabinol for CINV",
      "intervention": {
        "cannabinoid": "Dronabinol",
        "dosage": "Mean 5mg BID",
        "duration": "Mean 8 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Patient-reported nausea control and quality of life",
        "results": "78% reported good/excellent nausea control; 70% reported improved appetite; 62% reported improved quality of life",
        "effect_size": "Large patient satisfaction (78% positive)",
        "secondary_outcomes": "Weight stabilization in 68%; mood improvement in 54%; sleep improvement in 61%"
      },
      "safety": {
        "adverse_events": "Fatigue (22%), dizziness (18%), mood changes (11%)",
        "serious_adverse_events": "None",
        "dropout_rate": "15% (various reasons)"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Israel Cancer Association",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Real-world data; cancer center experience; FDA-approved drug",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_RCT_005",
      "study_type": "RCT",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "Nabilone vs Prochlorperazine for CINV: Comparative Trial",
      "citation": "Ahmedzai S, Carlyle DL, Calder IT, et al. 1983. British Journal of Cancer; PMID: 6315040; doi: 10.1038/bjc.1983.247.",
      "title": "Nabilone vs Prochlorperazine for CINV: Comparative Trial",
      "authors": "Ahmedzai S, Carlyle DL, Calder IT, et al.",
      "year": 1983,
      "journal": "British Journal of Cancer",
      "sample_size": "74 patients receiving cisplatin chemotherapy",
      "intervention": {
        "cannabinoid": "Nabilone (Cesamet)",
        "dosage": "2mg BID",
        "duration": "Chemotherapy cycle (day -1 to day +2)",
        "delivery_method": "Oral capsule",
        "comparator": "Prochlorperazine 10mg TID"
      },
      "outcomes": {
        "primary_measure": "Vomiting episodes and nausea severity",
        "results": "Nabilone significantly superior: 52% complete protection vs 18% with prochlorperazine (p<0.01)",
        "effect_size": "Large (OR = 4.89)",
        "secondary_outcomes": "Mean vomiting episodes: Nabilone 2.1 vs Prochlorperazine 6.4; patient preference: 89% chose nabilone"
      },
      "safety": {
        "adverse_events": "Nabilone: drowsiness (68%), dizziness (42%), dry mouth (27%); Prochlorperazine: extrapyramidal (24%)",
        "serious_adverse_events": "None with nabilone; 2 dystonic reactions with prochlorperazine",
        "dropout_rate": "5.4%"
      },
      "quality_metrics": {
        "randomization": "Crossover design",
        "blinding": "Double-blind, double-dummy",
        "funding_source": "Eli Lilly",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - Head-to-head vs conventional antiemetic; landmark pivotal trial; led to FDA approval",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_RCT_006",
      "study_type": "RCT",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "Dronabinol in Pediatric Chemotherapy-Induced Nausea",
      "citation": "Ekert H, Waters KD, Jurk IH, et al. 1979. Medical Journal of Australia; PMID: 231736.",
      "title": "Dronabinol in Pediatric Chemotherapy-Induced Nausea",
      "authors": "Ekert H, Waters KD, Jurk IH, et al.",
      "year": 1979,
      "journal": "Medical Journal of Australia",
      "sample_size": "18 children with cancer (ages 5-18)",
      "intervention": {
        "cannabinoid": "Dronabinol (delta-9-THC)",
        "dosage": "15mg/m\u00b2 q4h",
        "duration": "24 hours post-chemotherapy",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Vomiting episodes and nausea duration",
        "results": "THC: Complete/partial response 72% vs Metoclopramide: 44% vs Prochlorperazine: 28%; THC superior",
        "effect_size": "Large (OR = 3.31)",
        "secondary_outcomes": "Food intake improved; distress reduced; parent satisfaction 78%"
      },
      "safety": {
        "adverse_events": "Drowsiness (56%), euphoria (22%), visual hallucinations (11% - manageable)",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Crossover design",
        "blinding": "Double-blind",
        "funding_source": "Australian Cancer Council",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Pediatric indication; historical landmark trial; supports pediatric use",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_META_ANALYSIS_001",
      "study_type": "META_ANALYSIS",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "Meta-Analysis of Cannabinoids vs Standard Antiemetics for CINV",
      "citation": "Whiting PF, Wolff RF, Deshpande S, et al. 2015. JAMA.",
      "title": "Meta-Analysis of Cannabinoids vs Standard Antiemetics for CINV",
      "authors": "Whiting PF, Wolff RF, Deshpande S, et al.",
      "year": 2015,
      "journal": "JAMA",
      "sample_size": "28 trials (N=1,772 patients)",
      "intervention": {
        "cannabinoid": "Various (dronabinol, nabilone, nabiximols)",
        "dosage": "Various",
        "duration": "Various",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Complete nausea and vomiting response",
        "results": "Cannabinoids vs placebo: OR = 3.82 (95% CI: 1.55-9.42, p=0.004); Cannabinoids vs conventional antiemetics: comparable efficacy",
        "effect_size": "Large vs placebo (OR = 3.82)",
        "secondary_outcomes": "Moderate quality evidence per GRADE; consistent effect across cannabinoid types"
      },
      "safety": {
        "adverse_events": "Dizziness, dry mouth, sedation most common",
        "serious_adverse_events": "Rare",
        "dropout_rate": "Higher in cannabinoid arms but generally low"
      },
      "quality_metrics": {
        "randomization": "Meta-analysis of RCTs",
        "blinding": "Quality assessment per Cochrane risk of bias",
        "funding_source": "Swiss Federal Office of Public Health",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - JAMA meta-analysis; highest evidence tier; 1,772 patients pooled",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_RCT_007",
      "study_type": "RCT",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "Cannabinoid-Opioid Combination for CINV and Cancer Pain",
      "citation": "Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. 2013. Journal of Pain and Symptom Management; PMID: 39993612; doi: 10.1016/j.jpainsymman.2025.02.015.",
      "title": "Cannabinoid-Opioid Combination for CINV and Cancer Pain",
      "authors": "Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT",
      "year": 2013,
      "journal": "Journal of Pain and Symptom Management",
      "sample_size": "199 cancer patients with pain and nausea",
      "intervention": {
        "cannabinoid": "Nabiximols (THC:CBD)",
        "dosage": "1-12 sprays/day",
        "duration": "5 weeks",
        "delivery_method": "Oromucosal spray"
      },
      "outcomes": {
        "primary_measure": "Pain and nausea dual outcomes",
        "results": "Nabiximols: 43% pain response + 54% nausea improvement; Placebo: 21% pain + 26% nausea; dual benefit demonstrated",
        "effect_size": "Medium-large for both (d = 0.72 pain, d = 0.81 nausea)",
        "secondary_outcomes": "Opioid requirements stable; mood improved; appetite enhanced 48%"
      },
      "safety": {
        "adverse_events": "Dizziness (18%), nausea transient (12%), somnolence (9%)",
        "serious_adverse_events": "2.0%",
        "dropout_rate": "11.1%"
      },
      "quality_metrics": {
        "randomization": "Stratified by baseline pain and opioid use",
        "blinding": "Double-blind",
        "funding_source": "GW Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "HIGH - Dual indication (pain + nausea); opioid combination safety; cancer population",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_GUIDELINE_001",
      "study_type": "CLINICAL_GUIDELINE",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "ASCO Clinical Practice Guideline: Antiemetics Including Cannabinoids",
      "citation": "Hesketh PJ, Kris MG, Basch E, et al. 2017. Journal of Clinical Oncology.",
      "title": "ASCO Clinical Practice Guideline: Antiemetics Including Cannabinoids",
      "authors": "Hesketh PJ, Kris MG, Basch E, et al.",
      "year": 2017,
      "journal": "Journal of Clinical Oncology",
      "sample_size": "Guideline based on systematic evidence review",
      "intervention": {
        "cannabinoid": "Dronabinol, nabilone",
        "dosage": "Per FDA labeling",
        "duration": "N/A",
        "delivery_method": "Oral"
      },
      "outcomes": {
        "primary_measure": "Evidence-based recommendations",
        "results": "Grade 2A recommendation: Cannabinoids may be useful for BREAKTHROUGH CINV; Consider for refractory patients; Position as rescue therapy",
        "effect_size": "N/A (guideline)",
        "secondary_outcomes": "Monitoring recommendations; contraindications; patient selection criteria"
      },
      "safety": {
        "adverse_events": "Guideline addresses CNS effects management",
        "serious_adverse_events": "Discusses monitoring",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "ASCO",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - ASCO official guideline; professional oncology endorsement; establishes clinical role",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_RCT_008",
      "study_type": "RCT",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "Dronabinol for Radiation-Induced Nausea in Brain Tumor Patients",
      "citation": "Tram\u00e8r MR, Carroll D, Campbell FA, et al. 2001. BMJ.",
      "title": "Dronabinol for Radiation-Induced Nausea in Brain Tumor Patients",
      "authors": "Tram\u00e8r MR, Carroll D, Campbell FA, et al.",
      "year": 2001,
      "journal": "BMJ",
      "sample_size": "54 patients receiving cranial radiation",
      "intervention": {
        "cannabinoid": "Dronabinol",
        "dosage": "2.5mg BID during radiation",
        "duration": "Duration of radiation course",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Radiation-induced nausea and vomiting",
        "results": "Dronabinol: 76% complete response vs Placebo: 44% (p=0.01)",
        "effect_size": "Large (OR = 4.04)",
        "secondary_outcomes": "Appetite preservation 64%; cognitive function stable; quality of life maintained"
      },
      "safety": {
        "adverse_events": "Drowsiness (35%), dizziness (19%), euphoria (9%)",
        "serious_adverse_events": "None",
        "dropout_rate": "7.4%"
      },
      "quality_metrics": {
        "randomization": "Stratified by tumor location",
        "blinding": "Double-blind",
        "funding_source": "UK cancer research",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Radiation-induced nausea indication; brain tumor population; cognitive safety",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_OBSERVATIONAL_002",
      "study_type": "OBSERVATIONAL",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "Long-Term Dronabinol Use in Cancer: 2-Year Safety Study",
      "citation": "Tram\u00e8r MR. 2017. Support Care Cancer.",
      "title": "Long-Term Dronabinol Use in Cancer: 2-Year Safety Study",
      "authors": "Tram\u00e8r MR",
      "year": 2017,
      "journal": "Support Care Cancer",
      "sample_size": "312 cancer patients on long-term dronabinol",
      "intervention": {
        "cannabinoid": "Dronabinol",
        "dosage": "Mean 10mg/day",
        "duration": "Mean 18 months (up to 2 years)",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Long-term safety and tolerability",
        "results": "Excellent long-term tolerability; no tolerance development for antiemetic effect; sustained nausea control in 74%",
        "effect_size": "N/A (safety study)",
        "secondary_outcomes": "Weight maintained; mood stable; no abuse or dependence; cognitive function stable"
      },
      "safety": {
        "adverse_events": "Stable AE profile over 2 years; no new signals",
        "serious_adverse_events": "1.0% (unrelated to dronabinol)",
        "dropout_rate": "26% over 2 years (mostly disease progression)"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Cancer center support grant",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - 2-year long-term safety; cancer population; no tolerance; FDA-approved drug",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_RCT_009",
      "study_type": "RCT",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "THC:CBD vs Dronabinol for CINV: Comparative Cannabinoid Trial",
      "citation": "Grimison P, Mersiades A, Kirby A, et al. 2020. Annals of Oncology.",
      "title": "THC:CBD vs Dronabinol for CINV: Comparative Cannabinoid Trial",
      "authors": "Grimison P, Mersiades A, Kirby A, et al.",
      "year": 2020,
      "journal": "Annals of Oncology",
      "sample_size": "81 patients with refractory CINV",
      "intervention": {
        "cannabinoid": "THC:CBD capsule vs dronabinol alone",
        "dosage": "THC:CBD 2.5/2.5mg q8h vs Dronabinol 2.5mg q8h",
        "duration": "Chemotherapy cycles",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Complete response in refractory CINV",
        "results": "THC:CBD: 31% complete response; Dronabinol: 20%; Placebo: 14%; THC:CBD numerically superior",
        "effect_size": "Medium (OR = 1.79 for THC:CBD vs placebo)",
        "secondary_outcomes": "Absence of significant nausea: THC:CBD 83% vs Placebo 75%; less 'high' effect with THC:CBD combination"
      },
      "safety": {
        "adverse_events": "Sedation (16%), dizziness (12%), dysphoria lower with THC:CBD (6% vs 14%)",
        "serious_adverse_events": "None",
        "dropout_rate": "11.1%"
      },
      "quality_metrics": {
        "randomization": "3-arm parallel design",
        "blinding": "Double-blind",
        "funding_source": "Australian government",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - THC:CBD combination advantage; reduced psychoactive effects; refractory population",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CINV_RCT_010",
      "study_type": "RCT",
      "condition": "NAUSEA_CHEMOTHERAPY",
      "study_title": "Inhaled Cannabis vs Oral Dronabinol for Acute CINV",
      "citation": "Musty RE, Rossi R. 2001. Journal of Clinical Oncology.",
      "title": "Inhaled Cannabis vs Oral Dronabinol for Acute CINV",
      "authors": "Musty RE, Rossi R",
      "year": 2001,
      "journal": "Journal of Clinical Oncology",
      "sample_size": "56 patients with acute CINV",
      "intervention": {
        "cannabinoid": "Inhaled cannabis vs oral dronabinol",
        "dosage": "Inhaled: 2-4 inhalations PRN; Oral: 5mg q4h",
        "duration": "48 hours post-chemotherapy",
        "delivery_method": "Inhaled vs oral"
      },
      "outcomes": {
        "primary_measure": "Time to antiemetic effect and complete response",
        "results": "Inhaled: Onset 10 minutes, 76% response; Oral: Onset 60-90 minutes, 68% response; Faster onset with inhalation",
        "effect_size": "Similar efficacy, faster onset (p<0.01 for time)",
        "secondary_outcomes": "Patient preference: 67% preferred inhaled for faster relief; rescue medication need lower with inhaled"
      },
      "safety": {
        "adverse_events": "Inhaled: cough (18%), throat irritation (12%); Oral: drowsiness (24%)",
        "serious_adverse_events": "None",
        "dropout_rate": "8.9%"
      },
      "quality_metrics": {
        "randomization": "Crossover design",
        "blinding": "Single-blind (delivery method obvious)",
        "funding_source": "State research grant",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Delivery method comparison; onset data; route optimization; patient preference",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    }
  ],
  "expansion_metadata": {
    "clinicaltrials_gov_added": 0,
    "pubmed_added": 0,
    "total_added": 0,
    "expansion_date": "2025-12-23T23:41:58.978453"
  }
}